title: Similar efficacy following four weeks treatment of asthmatics with formoterol 12 micrograms b.d. delivered by two different dry powder inhalers: differences in inhaler handling.
abstract: This randomised, multicentre, parallel-group study compared the clinical efficacy and ease of handling of two dry powder inhalers delivering the long-acting beta 2-agonist formoterol. After run-in, 200 asthmatics on treatment with inhaled corticosteroids and still presenting with suboptimal asthma control were randomised to receive 12 micrograms formoterol twice daily via either the Aerolizer inhaler (Foradil Aerolizer) or the Turbuhaler inhaler (Oxis Turbuhaler) for four weeks. Study variables included the mean morning pre-medication peak expiratory flow (PEF) during the last seven days of treatment and the correct inhaler handling according to inhaler-specific checklists. The mean difference in the effect on morning pre-medication PEF was 13.86 l/min in favour of formoterol via the Aerolizer inhaler (90% confidence interval 2.50, 25.21) in the intent-to-treat population. Eighty-six per cent of the patients under treatment with formoterol via the Turbuhaler inhaler performed correctly all the essential inhalation manoeuvres, whereas 98% of those on the Aerolizer inhaler did so. These results strongly suggest similar clinical efficacy with twice daily treatment of formoterol 12 micrograms metered dose delivered either by the Aerolizer, or the Turbuhaler device. They also suggest that handling the Aerolizer is easier than that of the Turbuhaler.
authors.affiliation: Department of Pulmonary Disease, Kaplan Hospital, Rehovot, Israel.
authors.forename: A
authors.initials: A
authors.lastname: Eliraz
authors.forename: A
authors.initials: A
authors.lastname: Ramirez-Rivera
authors.forename: P
authors.initials: P
authors.lastname: Ferranti
authors.forename: R
authors.initials: R
authors.lastname: Holzer
authors.forename: J M
authors.initials: JM
authors.lastname: García
authors.forename: C
authors.initials: C
authors.lastname: Turcotte
authors.forename: G
authors.initials: G
authors.lastname: Rapatz
authors.forename: P
authors.initials: P
authors.lastname: Pfister
authors.forename: T
authors.initials: T
authors.lastname: Overend
authors.forename: J
authors.initials: J
authors.lastname: Kottakis
mesh_terms: D000280:Administration, Inhalation; D000293:Adolescent; D000328:Adult; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000008:administration & dosage*; D004983:Ethanolamines / Q000008:administration & dosage*; D005260:Female; D005541:Forced Expiratory Volume / Q000502:physiology; D000068759:Formoterol Fumarate; D006801:Humans; D008297:Male; D008875:Middle Aged; D009330:Nebulizers and Vaporizers / Q000592:standards; D017060:Patient Satisfaction; D010366:Peak Expiratory Flow Rate / Q000502:physiology; D016896:Treatment Outcome
chemical_list: D001993:Bronchodilator Agents; D004983:Ethanolamines; D000068759:Formoterol Fumarate